Phase 1 N=38 Bioequivalence Study of Paroxetine and PAXIL Under Fasting Conditions in Healthy Mexican Participants
Anxiety Disorders
Primary: Maximum Observed Plasma Concentration (Cmax) of Paroxetine — 8.39; 8.83 Nanograms per milliliter
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=47 Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer
Metastatic Breast Cancer · Solid Tumors
Primary: The Maximum Tolerated Dose (MTD) in the Combination of MLN0128 and Alisertib in Patients With Advanced Solid Tumors Measured by Treatment Adverse Events as Assessed by…
Phase 1 N=23 Autologous Muscle Derived Cells for Underactive Bladder
Urinary Retention · Urinary Incontinence
Primary: Number of Participants With Study-related Adverse Events at 6 Months — 2; 1; 1; 1 participants
Phase 1 N=27 Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants
Rheumatoid Arthritis
Primary: Pharmacokinetic (PK) Parameter: AUClast of ATV, PRA, and ROS — 78.8; 70.2; 199.5; 232.5 h*ng/mL
Phase 1 N=39 Intravenous Fosfomycin Pharmacokinetics Study
Bacterial Infection · Multiple-drug Resistance · Pathogen Resistance
Primary: Area Under the Concentration-time Curve (AUC 0-8 and AUC 0-inf ) of ZTI-01 — 780.9; 959.4; 1086.0 h*ug/mL
Phase 1 N=19 Electrical Stimulation for Critically Ill Covid-19 Patients
Covid19 · Muscle Atrophy · Muscle Weakness
Primary: Change in Gastrocnemius Muscle Endurance (Muscle Sustained Contraction) in Response to Electrical Stimulation — 352; 323 milliVolts
Phase 1 N=15 T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
Breast Cancer
Primary: Hematological - Dose Limiting Toxicities — 1; 3; 7; 1 participants
Phase 1 N=23 A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder
Opioid Use Disorder
Primary: Number of Participants With Adverse Events (AEs) — 16; 6; 7; 6 Participants
Phase 1 N=36 A Single Dose Study About the Influence of Food on the Oral Bioavailability of Ladarixin Capsule in Healthy Volunteers
no Condition
Primary: Cmax of Plasma DF 2156Y — 67.345; 95.982 μg/mL — p=<0.0001
Phase 1 N=24 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose and Multiple Doses With Titration of TAK-935 in Healthy Japanese Participants
Healthy Volunteer
Primary: Parts 1 and 2: Percentage of Participants With at Least One Treatment-emergent Adverse Event (TEAE) — 0; 0; 0; 0 percentage of participants
Phase 1 N=34 Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)
Neoplasms · Carcinoma, Non-Small-Cell Lung
Primary: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0…
Phase 1 N=19 Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer
Colorectal Neoplasms
Primary: Number of Patients With Dose-Limiting Toxicities (DLT) — 0; 2; 0; 0 Participants
Phase 1 N=53 Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors
Neoplasms
Primary: Number of Participants With Worst Grade 2 or Higher Adverse Events Occurring in >5% of Participants at Least Possibly Related to Study Drugs — 1; 0; 0; 0 Participants
Phase 1 N=30 Modeling Mood Course to Detect Markers for Effective Adaptive Interventions- Aim 3
Bipolar Disorder · Psychosocial Intervention
Primary: Number of Shortened YMRS Surveys Completed — 1651 completed surveys
Phase 1 N=241 Flublok or Fluzone With Advax-CpG55.2 or AF03
Influenza · Influenza Immunisation
Primary: Number of Participants Reporting Local and Systemic Solicited Reactogenicity Events Post First Vaccination — 24; 25; 23; 23 Participants